SCHEMBL4881338

SCHEMBL4881338

O=S(=O)(Cl)c1ccc(Nc2nccc(Nc3ccc(F)c(Cl)c3)n2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.56
CA2 P00918 5/20 0.56
CA12 O43570 1/20 0.56
CA9 Q16790 1/20 0.56
CDK2 P24941 2/20 0.54
CDK4 P11802 1/20 0.54
CCNE1 P24864 1/20 0.54
MAPK1 P28482 2/20 0.53
MEN1 O00255 1/20 0.53
NPC1 O15118 1/20 0.53
LMNA P02545 1/20 0.53
MAPT P10636 1/20 0.53
ALOX12 P18054 1/20 0.53
RAB9A P51151 1/20 0.53
KMT2A Q03164 1/20 0.53
AURKA O14965 5/20 0.53
AURKB Q96GD4 2/20 0.53
SOS1 Q07889 1/20 0.52
KDR P35968 3/20 0.49
APP P05067 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4884494 0.99 CA1 (0.55) CA1CA2CA12CA9CDK2
SCHEMBL13392346 0.90 CDK2 (0.56) CA1CA2CDK2CDK4CCNE1
Hydrochloric Acid SCHEMBL3300332 0.89 CDK2 (0.55) CA1CA2CDK2CDK4CCNE1
SCHEMBL657412 0.89 MAPK1 (0.62) CDK2MAPK1MEN1NPC1LMNA
Hydrochloric Acid SCHEMBL27735100 0.88 AURKA (0.57) CA1CA2CA12CA9CDK2
SCHEMBL14020165 0.87 CDK2 (0.59) CA1CA2CDK2CDK4CCNE1
SCHEMBL3197568 0.86 MAPK1 (0.73) CDK2MAPK1MEN1NPC1LMNA
Hydrochloric Acid SCHEMBL3304512 0.86 CDK2 (0.58) CA1CA2CDK2CDK4CCNE1
SCHEMBL13392205 0.85 NPC1 (0.75) CA1CA2CDK2CDK4CCNE1
Hydrochloric Acid SCHEMBL3299181 0.84 NPC1 (0.73) CA1CA2CDK2CDK4CCNE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors SANOFI-AVENTIS (FR) 2008-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269170-A1 Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors NFKBIA, IKBKB, IKBKE CA1 4640/4885CA2 3293/4885CA12 4820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.